Biogen and the badly needed gene therapy acquisition that got away – STAT
STAT |
Biogen and the badly needed gene therapy acquisition that got away
STAT ast July, Biogen (BIIB 1) executives unveiled a new, more aggressive business development plan. Cash thrown off by the biotech's maturing but still very profitable multiple sclerosis franchise would be redeployed to license or acquire new neuroscience … |
